American Herbal Products Association (AHPA) > News > Alerts > Legal Alerts

Legal Alerts

AHPA NDI Database shows 15 of 59 most recent NDI notifications acknowledged by FDA without objection

18 NDI notifications were considered incomplete

Fifteen (or roughly 25 percent) of the 59 New Dietary Ingredient (NDI) notifications submitted to the Food and Drug Administration (FDA) between November 2015 and October 2016 were acknowledged without objection, according to the latest data uploaded to AHPA's NDI Database.

AHPA adopts labeling guidance for fungi products

Guidance becomes effective March 9, 2019

The Board of Trustees of the American Herbal Products Association (AHPA) at its March 9, 2017 meeting authorized issuance of guidance for labeling products that contain fungi ingredients.

AHPA expresses support for synthetic cannabinoids being placed into schedule I

AHPA submits comments to DEA

The American Herbal Products Association (AHPA) expressed strong support for the Drug Enforcement Agency (DEA) using its temporary scheduling authority to place synthetic cannabinoids into schedule I in comments submitted to the agency.

IADSA update on international supplement regulations

IADSA December 2016 Newsflash

This issue of the IADSA Newsflash includes an update on the Association of Southeast Asian Nations (ASEAN) Agreement on Regulatory Framework for Health Supplements deadline for implementation, which will be pushed back to March 2023.

FSMA Direct Impacts to Most AHPA Members

Regulatory experts provide a road map to FSMA understanding requirements and compliance

Webinar recorded Dec. 15, 2016. Member cost: $199. Nonmember cost: $499.

FDA Inspections, Warning Letters and Emerging cGMP Compliance Issues

Learn the elements of 21 CFR 111 / current Good Manufacturing Practice (cGMP) regulations that FDA inspections have been focusing on recently

Webinar recorded Dec. 13, 2016. Member cost: $199. Nonmember cost: $499.

AHPA submits comments to FDA on revised NDI draft guidance

Draft NDI guidance fails to achieve FDA's stated goals and is contrary to intent of the law

In comments submitted to the Food and Drug Administration (FDA), the American Herbal Products Association (AHPA) expressed concern that the latest revision of draft guidance for New Dietary Ingredients (NDIs) is unlikely to achieve FDA's stated goals and is contrary to the intent of the law in numerous areas.

AHPA submits comments to DEA on potential impacts of scheduling herbal constituents

DEA should avoid restricting research on new medical uses, health benefits, or other uses for botanicals

In comments submitted last week to the Drug Enforcement Agency (DEA), the American Herbal Products Association (AHPA) urged the agency to refrain from using its authority to effectively remove a plant from the existing marketplace because naturally occurring constituents become scheduled under the Controlled Substances Act (CSA).

AHPA submits comments to FTC regarding consumer perceptions of "organic" claims

Many personal care products and dietary supplements are produced in compliance with USDA's National Organic Progam

AHPA stressed that non-food products, including personal care products, may be agricultural products that can comply with the United States Department of Agriculture (USDA) National Organic Program (NOP).

AHPA submits vinpocetine comments to FDA

HHS Secretary has authority to create exceptions to dietary supplement definition

The American Herbal Products Association (AHPA) recommends the Secretary of Health and Human Services (HHS) consider initiating rulemaking to declare vinpocetine to be lawful dietary ingredient in comments submitted to the Food and Drug Administration (FDA).
RSS
12345678910 Last

2017 Annual Fund Sponsors

           

AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.